BBNX — Beta Bionics, Inc. Stock Price, Chart & AI Report

Negative Feb 17, 2026 • 22:00 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beta Bionics, Inc. - BBNX

Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in Beta Bionics, CVRx, and Navan. Beta Bionics experienced a significant stock price decline of 37% following the announcement of slower-than-expected patient growth in Q4 2025, with new patient starts increasing 36% year-over-year compared to 68% in the prior quarter.

BBNX CVRX NAVN securities fraud class action lawsuit investor investigation stock price decline financial results

Sentiment note

Company faces securities fraud investigation and experienced a sharp 37% stock price decline following disappointing patient growth metrics that fell significantly short of prior quarter performance.

Negative Feb 4, 2026 • 01:24 UTC GlobeNewswire Inc. • Faruqi & Faruqi, Llp

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics

Securities law firm Faruqi & Faruqi is investigating Beta Bionics for potentially issuing misleading statements or failing to disclose material information to investors. The investigation was prompted by a 37% stock plunge on January 9, 2026, following the company's announcement of lower-than-expected patient starts in Q4.

BBNX securities litigation Beta Bionics stock decline investor losses misleading statements disclosure failure

Sentiment note

The company experienced a significant 37% stock price decline following disappointing guidance on patient starts. A securities investigation into potential misleading statements and disclosure failures further indicates serious concerns about the company's credibility and financial performance.

Negative Jan 21, 2026 • 23:15 UTC GlobeNewswire Inc. • Scott+Scott Attorneys At Law Llp

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Beta Bionics, Inc. (NASDAQ: BBNX)

Scott+Scott is investigating whether Beta Bionics issued misleading statements or failed to disclose material information to investors. The company reported 5,581 new patient starts for Q4 2025, falling short of the 6,078 consensus expectation, causing the stock to plunge 37% to $20.14 on January 9, 2026.

BBNX securities litigation class action investigation misleading statements financial results stock decline medical device company investor losses

Sentiment note

The company missed analyst consensus expectations for new patient starts (5,581 vs. 6,078 expected), resulting in a significant 37% stock price decline. Additionally, a securities investigation has been initiated into potential misleading statements or disclosure failures, indicating serious concerns about the company's communications with investors.

Negative Jan 15, 2026 • 06:36 UTC Benzinga • Prnewswire

Beta Bionics, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - BBNX

The DJS Law Group is investigating Beta Bionics (NASDAQ: BBNX) for potential securities law violations, alleging the company issued misleading statements or failed to disclose material information. The investigation was triggered after Beta Bionics announced lower-than-expected patient starts for Q4 on January 8, 2026, causing the stock to plummet 37% the following day.

BBNX securities investigation misleading statements patient starts stock decline class action investor losses

Sentiment note

The company faces a securities investigation for potential disclosure violations and misleading statements. The announcement of lower patient starts resulted in a severe 37% stock price decline, indicating significant investor concern and potential financial impact on shareholders.

Negative Jan 14, 2026 • 17:53 UTC GlobeNewswire Inc. • The Schall Law Firm

BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm is investigating Beta Bionics, Inc. for potential securities law violations, alleging the company issued false or misleading statements regarding patient starts. Beta Bionics disclosed lower-than-expected patient numbers on January 8, 2026, causing its stock to plummet over 37% the following day. The firm is seeking shareholders who suffered losses to participate in the investigation.

BBNX securities fraud shareholder litigation Beta Bionics stock decline misleading statements patient starts class action lawsuit

Sentiment note

The company is under investigation for potential securities fraud involving false or misleading disclosures about patient starts. The stock experienced a severe 37% decline following the announcement of lower-than-expected patient numbers, indicating significant loss of investor confidence and potential regulatory violations.

Negative Jan 12, 2026 • 21:55 UTC Benzinga • Business Wire

Securities Fraud Investigation Into Beta Bionics, Inc. (BBNX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announced an investigation into Beta Bionics, Inc. for possible federal securities law violations. The investigation was triggered after Beta Bionics reported preliminary Q4 2025 results showing new patient starts growth of 36% year-over-year, down significantly from 68% in the prior quarter. The stock fell 37% ($11.85) to $20.15 per share on January 9, 2026, following the announcement.

BBNX securities fraud investigation Beta Bionics patient starts decline stock price decline Q4 2025 results investor losses

Sentiment note

The company faces a securities fraud investigation, reported a significant slowdown in patient growth metrics (36% vs. 68% prior quarter), and experienced a severe 37% stock price decline, resulting in investor losses.

Negative Jan 12, 2026 • 12:15 UTC Benzinga • Business Wire

Beta Bionics, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – BBNX

The DJS Law Group is investigating Beta Bionics (NASDAQ: BBNX) for potential securities law violations, alleging the company issued misleading statements or failed to disclose material information. The investigation was triggered after Beta Bionics announced lower-than-expected patient starts for Q4 2025, causing the stock to plummet 37% on January 9, 2026.

BBNX securities investigation misleading statements patient starts stock decline class action biotech

Sentiment note

The company faces a securities investigation for potential disclosure violations and misleading statements. The significant 37% stock price drop following the announcement of lower patient starts indicates serious investor concerns about the company's performance and transparency.

Negative Jan 10, 2026 • 22:23 UTC Benzinga • Business Wire

BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm is investigating Beta Bionics, Inc. (NASDAQ: BBNX) for potential securities law violations, alleging the company issued false or misleading statements regarding patient starts. Beta Bionics disclosed lower-than-expected patient start numbers on January 8, 2026, causing its stock to plummet more than 37% the following day. The firm is seeking investors to join the class action lawsuit.

BBNX fraud investigation securities violation class action lawsuit patient starts stock decline misleading statements

Sentiment note

The company faces a fraud investigation for allegedly issuing false or misleading statements about patient starts. The stock experienced a severe 37% decline following the disclosure of lower-than-expected patient numbers, indicating significant loss of investor confidence and potential legal liability.

Positive Jun 18, 2025 • 17:00 UTC GlobeNewswire Inc. • Delveinsight

Global Artificial Pancreas Devices Market is Gearing Up for Outstanding Expansion at a CAGR of ~16% by 2032 | DelveInsight

The global artificial pancreas devices market is expected to grow significantly due to the rising prevalence of diabetes, increased awareness, and ongoing product innovations by leading companies.

BBNX DXCM artificial pancreas devices diabetes medical devices market growth

Sentiment note

Beta Bionics, Inc. is one of the key companies operating in the artificial pancreas devices market, supporting the market expansion.

Neutral Jun 2, 2025 • 12:11 UTC Benzinga • Vandana Singh

Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges

Goldman Sachs is bullish on Dexcom and Insulet, citing their strong positions in the growing diabetes technology market. The firm is neutral on newly listed Beta Bionics, noting its early adoption phase.

DXCM PODD BBNX Dexcom Insulet Beta Bionics diabetes technology

Sentiment note

Goldman Sachs initiated coverage with a Neutral rating and a $16 price target, noting that Beta Bionics' iLet technology is still in the early adoption phase.

Positive Jan 31, 2025 • 22:56 UTC GlobeNewswire Inc. • N/A

Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Beta Bionics, a medical device company, has successfully completed its initial public offering, raising $234.6 million. The company's shares began trading on the Nasdaq under the ticker symbol 'BBNX'.

BBNX Beta Bionics IPO Nasdaq medical device

Sentiment note

The article reports on the successful completion of Beta Bionics' initial public offering, which raised a significant amount of capital and allowed the company's shares to start trading on the Nasdaq. This suggests the company is in a strong position to continue its growth and development of innovative diabetes management solutions.